Boceprevir for patients with prior failure to peg rib provide
This presentation is the property of its rightful owner.
Sponsored Links
1 / 6

Boceprevir for Patients with Prior Failure to PEG + RIB PROVIDE PowerPoint PPT Presentation


  • 90 Views
  • Uploaded on
  • Presentation posted in: General

Phase 3. Treatment Experienced. Boceprevir for Patients with Prior Failure to PEG + RIB PROVIDE. Vierling JM, et al. J Hepatol . 2013;Dec 19 [ Epub ahead of print]. Boceprevir for Patients with Prior Failure to PEG + RIB PROVIDE Study: Features.

Download Presentation

Boceprevir for Patients with Prior Failure to PEG + RIB PROVIDE

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


Boceprevir for patients with prior failure to peg rib provide

Phase 3

TreatmentExperienced

Boceprevir for Patients with Prior Failure to PEG + RIBPROVIDE

Vierling JM, et al. J Hepatol. 2013;Dec 19 [Epub ahead of print].


Boceprevir for patients with prior failure to peg rib provide study features

Boceprevir for Patients with Prior Failure to PEG + RIBPROVIDE Study: Features

Drug DosingBoceprevir = 800 mg three times dailyPeginterferon alfa-2b = 1.5 µg/kg once weeklyRibavirin = 600-1400 mg/day (based on weight)

Source: VierlingJM, et al. J Hepatol. 2013;Dec 19 [Epub ahead of print].


Boceprevir for patients with prior failure to peg rib provide study treatment regimens

Boceprevir for Patients with Prior Failure to PEG + RIBPROVIDE Study: Treatment Regimens

Week

0

4

8

12

24

36

44

48

Patients who enrolled within 2 weeks after ending/completing previous treatment with PR

B44

PR44

Boceprevir

Peginterferon + Ribavirin

Patients who enrolled ≥ 2 weeks after ending/completing their previous treatment with PR

Boceprevir

B44PR48

Peginterferon + Ribavirin

Lead In

Source: Vierling JM, et al. J Hepatol. 2013;Dec 19 [Epub ahead of print].


Boceprevir for patients with prior failure to peg rib provide study results

Boceprevir for Patients with Prior Failure to PEG + RIBPROVIDE Study: Results

PROVIDE: SVR 24 by Prior Response (mITT)

106/164

20/49

57/85

27/28

SVR = Sustained Virologic Response; mITT = modfied intent to treat analysis

Source: Vierling JM, et al. J Hepatol. 2013;Dec 19 [Epub ahead of print].


Boceprevir for patients with prior failure to peg rib provide study conclusions

Boceprevir for Patients with Prior Failure to PEG + RIBPROVIDE Study: Conclusions

Source: Vierling JM, et al. J Hepatol. 2013;Dec 19 [Epub ahead of print].


Boceprevir for patients with prior failure to peg rib provide

This slide deck is from the University of Washington’s Hepatitis C Online and Hepatitis Web Study projects.

Hepatitis C Onlinewww.hepatitisc.uw.edu

Hepatitis Web Studyhttp://depts.washington.edu/hepstudy/

Funded by a grant from the Centers for Disease Control and Prevention.


  • Login